Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 15/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392780 | 1.00 | CCR3 (0.62) | CCR3SIGMAR1CYP2D6DRD2SLC6A2 | |
| Hydrochloric Acid SCHEMBL4435343 | 0.99 | CCR3 (0.61) | CCR3SIGMAR1CYP2D6DRD2SLC6A2 | |
| SCHEMBL4424225 | 0.89 | CCR3 (0.56) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14392538 | 0.89 | CCR3 (0.56) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4424272 | 0.83 | CCR3 (0.53) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14392539 | 0.83 | CCR3 (0.53) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4563405 | 0.80 | CCR3 (0.44) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL5659781 | 0.79 | CCR3 (0.52) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14392548 | 0.79 | CCR3 (0.52) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4434871 | 0.78 | CCR3 (0.47) | CCR3CYP2D6DRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | CCR3 247/4885SIGMAR1 3/4885CYP2D6 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.